Niacin/lovastatin

From Wikipedia, the free encyclopedia
Niacin/lovastatin
Combination of
Niacin Vitamin
Lovastatin Statin
Clinical data
Pregnancy cat. X (US)
Legal status ℞-only (US)
Routes Oral
Identifiers
ATC code C10BA01
 YesY (what is this?)  (verify)

Niacin/lovastatin (trade names Advicor, Mevacor) is a drug combination used for the treatment of dyslipidemia. It is a combination of the vitamin niacin and the statin drug lovastatin. The combination preparation is marketed by Abbott Laboratories

It was approved by the FDA on December 17, 2001.

Dosage

The combination is available as tablets containing:.[1]

  • 500 mg/20 mg
  • 750 mg/20 mg
  • 1000 mg/20 mg
  • 1000 mg/40 mg

References

  1. ↑ "Advicor package insert, How Supplied section". Retrieved 2008-03-15. 

External links

Lipid modifying agents (C10)
GI tract
Cholesterol absorption inhibitors, NPC1L1
  • Ezetimibe
  • SCH-48461
Bile acid sequestrants/resins (LDL)
  • Cholestyramine
  • Colestipol
  • Colestilan
  • Colextran
  • Colesevelam
Liver
Statins (HMG-CoA reductase, LDL)
  • Simvastatin#
  • Atorvastatin
  • Fluvastatin
  • Lovastatin
  • Mevastatin
  • Pitavastatin
  • Pravastatin
  • Rosuvastatin
  • Cerivastatin‡
Niacin and derivatives (HDL and LDL)
  • Niceritrol
  • Niacin
  • Nicofuranose
  • Aluminium nicotinate
  • Nicotinyl alcohol
  • Acipimox
MTTP inhibitors (VLDL)
  • Dirlotapide
  • Lomitapide
  • Mitratapide
Blood vessels
Fibrates (PPAR)
  • Clofibrate‡
  • Bezafibrate
  • Aluminium clofibrate
  • Gemfibrozil
  • Fenofibrate
  • Simfibrate
  • Ronifibrate
  • Ciprofibrate
  • Etofibrate
  • Clofibride
  • Clinofibrate
CETP inhibitors (HDL)
  • Anacetrapib†
  • Dalcetrapib§
  • Evacetrapib§
  • Torcetrapib†
Combinations
  • Niacin/lovastatin
  • Niacin/simvastatin
  • Ezetimibe/simvastatin
  • Ezetimibe/atorvastatin
  • Niacin/laropiprant
Other
  • Dextrothyroxine‡
  • Probucol
  • Tiadenol
  • Benfluorex
  • Meglutol
  • Omega-3-triglycerides
  • Magnesium pyridoxal 5-phosphate glutamate
  • Policosanol
  • Lapaquistat§
  • Mipomersen
  • Alipogene tiparvovec
  • #WHO-EM
  • ‡Withdrawn from market
  • Clinical trials:
    • †Phase III
    • §Never to phase III

M: MET

mt, k, c/g/r/p/y/i, f/h/s/l/o/e, a/u, n, m

k, cgrp/y/i, f/h/s/l/o/e, au, n, m, epon

m (A16/C10), i (k, c/g/r/p/y/i, f/h/s/o/e, a/u, n, m)


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.